The acute effects of Yohimbine on fear conditioning and the neural processing of emotional images, and on delayed extinction learning and memory for the images.
An Analysis of Sex Differences in the Effects of Yohimbine on Fear Conditioning and on the Encoding of Emotional Memory in Healthy Participants: A Randomised Placebo-Controlled Trial
University of New South Wales
120 participants
Feb 1, 2012
Interventional
Conditions
Summary
This study aims to examine sex differences in the effects of Yohimbine on the neural processing of, and delayed memory for, emotional images. Sex differences will also be explored in the effects of Yohimbine on fear conditioning, and whether this impacts the rate of extinction learning after a delay. Participants will be randomly assigned to recieve either Yohimbine or Placebo. Participants will first undergo a fear conditioning procedure in which they will be presented with coloured circles and a particular colour will be paired with a mild electrical stimulus. Rate of conditioning (or associative fear learning) will be measured via skin conductance responses across trials. Subsequently, in an fMRI scanning machine, all participants will view a series of emotional and neutral images. Two days later, participants will return and undergo a surprise memory test for the images. Following the memory tests, participants will undergo an extinction learning procedure in which skin conductance will be recorded across trials in which the same circles will be presented without any reinforcement (electrical stimulus). The hypothesis is that Yohimbine will enhance amydgala activation during the processing of emotional images, and be associated with superior memory for the emotional images. It is predicted that Yohimbine will enhance the rate of fear conditioning, particularly in women. It is also predicted that the administration of Yohimbine will result in strong amygdala activation during the processing of emotional images as well as the deactivation of prefrontal regions of the brain in participants with higher levels of endogenous cortisol. Finally, it is believed that participants in the Yohimbine group will experience a slower rate of extinction learning after the delay (and particularly in women). All participants and research staff will be blind to the drug contition of the subject until after the study is completed.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Healthy male and female participants are either given Yohimbine (20mg) or placebo pill via oral administration. Participants then undergo a fear acquisition paradigm in which they will be shown images of blue and red circles. In a counter-balanced order, one set of coloured circles will be paired with a mild electrical stimulus applied to participants' fingertips at an intensity selected by the participant to be "uncomfortable but not painful". Skin conductance will be used as a measure of conditioned response to the stimuli. Participants will then undergo a functional magnetic resonance imaging scan (fMRI) where they will view emotional and neutral images. They return two days later to complete surprise recall and recognition memory tasks for the images. At this second session, participants will also undergo a fear extinction paradigm in which they will be presented with the blue and red circles without aversive reinforcement. Skin conductance will again be recorded during this procedure.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12611000820909